Windsor, Brian

LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices from patients with IPF

MacKenzie, B., Mahavadi, P., Pinho Jannini-Sa, Y. A., Creyns, B., Coelho, A. L., Espindola, M., Ruppert, C., Windsor, B., Aigner, C., Hogaboam, C. M., et al. (2025) · iScience

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 2

Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study

Molyneaux, P. L., Hirani, N. A., Chia, C. C. K., Kulkarni, T., Zaman, T., Kaner, R. J., Coelho, A. L., Jannini-Sa, Y. A. P., Windsor, B., Kruger, S., et al. (2026) · Nature Communications

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 1

Caveolin Scaffolding Domain LTI-03 Modulates Both Inflammatory and Fibrotic Responses in Aged Mice After Bleomycin Challenge

Mackenzie, B., Maier, E., Creyns, B., Coelho, A. L., Windsor, B., & Hogaboam, C. M. (2022) · A107. MECHANISMS OF FIBROSIS/FIBROBLAST BIOLOGY

Caveolin-1 and cellular processesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 0